WILEX AG

 

 

ENGLISH DEUTSCH

Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.

 

Latest News

11.05.2017: Press release: WILEX AG successfully completes rights issue....More

More information on the capital increase can be found here.

 

 

 

Seite gelesen: 74481 | Heute: 56